NCT07550790 Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
| NCT ID | NCT07550790 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jin Joo Park |
| Condition | Heart Failure Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 190 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 190 participants in total. It began in 2026-07-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.
Eligibility Criteria
Inclusion Criteria: * Adults aged 20 years or older * Emergency department visit/hospitalization for acute heart failure with clinical evidence of congestion * Planned contrast-enhanced computed tomography during the index hospitalization * Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL/min/1.73 m² Exclusion Criteria: * Requirement for vasopressor therapy * Requirement for renal replacement therapy (dialysis) * Known allergy or hypersensitivity to furosemide * Ongoing acute coronary syndrome * Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test * Hyperkalemia (serum potassium \>5.5 mmol/L) * Uncorrected volume depletion or hyponatremia (serum sodium \<130 mmol/L) * Any condition deemed by the investigator to make participation in the study inappropriate
Contact & Investigator
Jin Joo Park, MD, PhD
PRINCIPAL INVESTIGATOR
Seoul National University Bundang Hospital
Frequently Asked Questions
Who can join the NCT07550790 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Heart Failure Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07550790 currently recruiting?
Yes, NCT07550790 is actively recruiting participants. Contact the research team at jinjooparkmd@snubh.org for enrollment information.
Where is the NCT07550790 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT07550790 clinical trial?
NCT07550790 is sponsored by Jin Joo Park. The principal investigator is Jin Joo Park, MD, PhD at Seoul National University Bundang Hospital. The trial plans to enroll 190 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.